The Solid Tumor Testing Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The market size of solid tumor testing has been increasing significantly in previous years. It is predicted to expand from $27.96 billion in 2024 to $30 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 7.3%.
The Solid Tumor Testing Global Market Report 2024 forecasts that by 2029, the market size will reach up to $40.06 billion, growing at a compound annual growth rate of 7.5%.
Download Your Free Sample of the 2025 Solid Tumor Testing Market Report and Uncover Key Trends Now!The key drivers in the solid tumor testing market are:
• Rising occurrences of cancer globally
• Development and improvement of healthcare infrastructure
• Emergence and adoption of AI and IoT-based diagnostic devices
• Increased government initiatives supporting healthcare and diagnostics
The solid tumor testing market covered in this report is segmented –
1) By Type: Genetic Testing, Conventional Testing
2) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer
3) By Application: Clinical, Research
4) By End-Users: Hospitals, Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic Research Institutions
The key trends in the solid tumor testing market are:
• Advancements in diagnostic tools is a key trend shaping the market.
• The introduction of nanocarrier-based therapies is emerging as a significant trend.
• Strategic collaborations are increasingly influencing the market future.
• The trend of next-generation testing devices is swiftly rising.
The major players in the solid tumor testing market are:
• Johnson & Johnson Ltd
• Roche Diagnostics Corporation
• Thermo Fisher Scientific Inc
North America was the largest region in the solid tumor testing market in 2024